FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

Over 50% of colorectal cancer (CRC) patients develop metastases. The aim of this study was to evaluate efficacy and tolerance of first-line FOLFIRI® + bevacizumab (B) treatment for metastatic CRC, and to assess genetic polymorphisms as potential markers. Adult patients with histologically-proven, no...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC research notes 2014-04, Vol.7 (1), p.260-260, Article 260
Hauptverfasser:	Bécouarn, Yves, Cany, Laurent, Pulido, Marina, Beyssac, Richard, Texereau, Patrick, Le Morvan, Valérie, Béchade, Dominique, Brunet, René, Aitouferoukh, Sofiane, Lalet, Caroline, Mathoulin-Pélissier, Simone, Fonck, Marianne, Robert, Jacques
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Camptothecin - adverse effects Camptothecin - analogs & derivatives Camptothecin - therapeutic use Cancer Chemotherapy Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Demography Diarrhea Disease-Free Survival Drug therapy Female Fluorouracil - adverse effects Fluorouracil - therapeutic use Genetic aspects Genetic polymorphisms Genotyping Techniques Humans Leucovorin - adverse effects Leucovorin - therapeutic use Life Sciences Male Medical research Medicine, Experimental Metastasis Multivariate Analysis Polymorphism, Genetic Studies Treatment Outcome Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!